-
1
-
-
82955247909
-
IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
-
Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321, 2011.
-
(2011)
Diabetes Res Clin Pract
, vol.94
, pp. 311-321
-
-
Whiting, D.R.1
Guariguata, L.2
Weil, C.3
Shaw, J.4
-
2
-
-
65449135133
-
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
-
Bosi E, Dotta F, Jia Y and Goodman M: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 11: 506-515, 2009.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 506-515
-
-
Bosi, E.1
Dotta, F.2
Jia, Y.3
Goodman, M.4
-
3
-
-
77953192546
-
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
-
Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A and Kothny W: An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 12: 495-509, 2010.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 495-509
-
-
Ligueros-Saylan, M.1
Foley, J.E.2
Schweizer, A.3
Couturier, A.4
Kothny, W.5
-
4
-
-
77949356196
-
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
-
Filozof C and Gautier JF: A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 27: 318-326, 2010.
-
(2010)
Diabet Med
, vol.27
, pp. 318-326
-
-
Filozof, C.1
Gautier, J.F.2
-
5
-
-
77955048324
-
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study
-
Matthews DR, Dejager S, Ahren B, et al: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12: 780-789, 2010.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 780-789
-
-
Matthews, D.R.1
Dejager, S.2
Ahren, B.3
-
6
-
-
78649711971
-
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: A pooled analysis from a database of clinical trials
-
Schweizer A, Dejager S, Foley JE, Shao Q and Kothny W: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 13: 55-64, 2011.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 55-64
-
-
Schweizer, A.1
Dejager, S.2
Foley, J.E.3
Shao, Q.4
Kothny, W.5
-
7
-
-
84896729541
-
Safety and efficacy of vildagliptin: Dipeptidyl peptidase-4 inhibitor
-
Patel B and Shah J: Safety and efficacy of vildagliptin: dipeptidyl peptidase-4 inhibitor. IJPRBS 2: 35-51, 2012.
-
(2012)
IJPRBS
, vol.2
, pp. 35-51
-
-
Patel, B.1
Shah, J.2
-
8
-
-
79960831855
-
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
-
Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE and Foley JE: Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13: 775-783, 2011.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 775-783
-
-
Ahrén, B.1
Schweizer, A.2
Dejager, S.3
Villhauer, E.B.4
Dunning, B.E.5
Foley, J.E.6
-
9
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:An algorithm for glycemic control
-
Rodbard HW, Jellinger PS, Davidson JA, et al: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:an algorithm for glycemic control. Endocrine Practice 15: 540-549, 2009.
-
(2009)
Endocrine Practice
, vol.15
, pp. 540-549
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
-
10
-
-
65449151804
-
The scientific evidence: Vildagliptin and the benefits of islet enhancement
-
Mathieu C: The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab 11 (Suppl 2): S9-S17, 2009.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.SUPPL. 2
-
-
Mathieu, C.1
-
11
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs. Glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
Ferrannini E, Fonseca V, Zinman B, et al: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11: 157-166, 2009.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
-
12
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
Bosi E, Camisasca RP, Collober C, Rochotte E and Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895, 2007.
-
(2007)
Diabetes Care
, vol.30
, pp. 890-895
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
Rochotte, E.4
Garber, A.J.5
-
13
-
-
36749024547
-
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
-
Ahrén B, Pacini G, Tura A, Foley JE and Schweizer A: Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 39: 826-829, 2007.
-
(2007)
Horm Metab Res
, vol.39
, pp. 826-829
-
-
Ahrén, B.1
Pacini, G.2
Tura, A.3
Foley, J.E.4
Schweizer, A.5
-
14
-
-
37349054435
-
Efficacy and tolerability of vildagliptin vs. Pioglitazone when added to metformin: A 24-week, randomized, double-blind study
-
Bolli G, Dotta F, Rochotte E and Cohen SE: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 10: 82-90, 2008.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 82-90
-
-
Bolli, G.1
Dotta, F.2
Rochotte, E.3
Cohen, S.E.4
-
15
-
-
65549131200
-
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
-
Bolli G, Dotta F, Colin L, Minic B and Goodman M: Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 11: 589-595, 2009.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 589-595
-
-
Bolli, G.1
Dotta, F.2
Colin, L.3
Minic, B.4
Goodman, M.5
-
16
-
-
58149385790
-
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting Islet-cell function in subjects with type 2 diabetes
-
D'Alessio DA, Denney AM, Hermiller LM, et al: Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting Islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94: 81-88, 2009.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 81-88
-
-
D'alessio, D.A.1
Denney, A.M.2
Hermiller, L.M.3
-
17
-
-
70349761649
-
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial - a primary care, type 2 diabetes study
-
Blonde L, Dagogo-Jack S, Banerji MA, et al: Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab 11: 978-986, 2009.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 978-986
-
-
Blonde, L.1
Dagogo-Jack, S.2
Banerji, M.A.3
-
18
-
-
78851471216
-
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
-
Ahrén B, Foley JE and Bosi E: Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 13: 193-203, 2011.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 193-203
-
-
Ahrén, B.1
Foley, J.E.2
Bosi, E.3
-
19
-
-
82855179439
-
Tolerability of dipeptidyl peptidase-4 inhibitors: A review
-
Richard KR, Shelburne JS and Kirk JK: Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 33: 1609-1629, 2011.
-
(2011)
Clin Ther
, vol.33
, pp. 1609-1629
-
-
Richard, K.R.1
Shelburne, J.S.2
Kirk, J.K.3
-
20
-
-
80052551137
-
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial
-
Lukashevich V, Schweizer A, Shao Q, Groop PH and Kothny W: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13: 947-954, 2011.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 947-954
-
-
Lukashevich, V.1
Schweizer, A.2
Shao, Q.3
Groop, P.H.4
Kothny, W.5
-
21
-
-
79955506305
-
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes
-
Kalra S: Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India 59: 237-245, 2011.
-
(2011)
J Assoc Physicians India
, vol.59
, pp. 237-245
-
-
Kalra, S.1
|